Q. Li

459 total citations
20 papers, 367 citations indexed

About

Q. Li is a scholar working on Immunology, Dermatology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Q. Li has authored 20 papers receiving a total of 367 indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Immunology, 6 papers in Dermatology and 5 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Q. Li's work include Psoriasis: Treatment and Pathogenesis (11 papers), Dermatology and Skin Diseases (6 papers) and Autoimmune Bullous Skin Diseases (4 papers). Q. Li is often cited by papers focused on Psoriasis: Treatment and Pathogenesis (11 papers), Dermatology and Skin Diseases (6 papers) and Autoimmune Bullous Skin Diseases (4 papers). Q. Li collaborates with scholars based in United States, Canada and Germany. Q. Li's co-authors include Kim Papp, Kristian Reich, Diamant Thaçi, Anish Mehta, Richard G. Langley, Hidemi Nakagawa, Yijie Zhou, James G. Krueger, Alice B. Gottlieb and Elisabeth Riedl and has published in prestigious journals such as Annals of Oncology, Annals of the Rheumatic Diseases and British Journal of Dermatology.

In The Last Decade

Q. Li

18 papers receiving 361 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Q. Li United States	6	318	221	91	65	41	20	367
Luigi Gargiulo Italy	13	237 0.7×	240 1.1×	78 0.9×	71 1.1×	62 1.5×	48	381
Giovanna Malara Italy	12	231 0.7×	159 0.7×	65 0.7×	44 0.7×	43 1.0×	26	347
Abby Jacobson United States	12	350 1.1×	253 1.1×	76 0.8×	64 1.0×	18 0.4×	52	386
Stephanie Mehlis United States	6	253 0.8×	151 0.7×	46 0.5×	53 0.8×	20 0.5×	14	310
Jai-Il Youn South Korea	6	244 0.8×	135 0.6×	48 0.5×	83 1.3×	20 0.5×	12	325
Hany Elmaraghy United States	9	261 0.8×	315 1.4×	82 0.9×	62 1.0×	13 0.3×	30	419
Achim Guettner Switzerland	8	436 1.4×	325 1.5×	109 1.2×	79 1.2×	26 0.6×	10	558
Christian Thoma Germany	10	464 1.5×	334 1.5×	158 1.7×	126 1.9×	30 0.7×	27	528
J. M. P. A. van den Reek Netherlands	11	346 1.1×	198 0.9×	66 0.7×	38 0.6×	29 0.7×	32	424

Countries citing papers authored by Q. Li

Since Specialization

Citations

This map shows the geographic impact of Q. Li's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Q. Li with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Q. Li more than expected).

Fields of papers citing papers by Q. Li

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Q. Li. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Q. Li. The network helps show where Q. Li may publish in the future.

Co-authorship network of co-authors of Q. Li

This figure shows the co-authorship network connecting the top 25 collaborators of Q. Li. A scholar is included among the top collaborators of Q. Li based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Q. Li. Q. Li is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Zhou, Kun, Hui Cai, Q. Li, et al.. (2025). Nobiletin protected against hypertrophic cardiomyopathy via targeting PPARα. Frontiers in Pharmacology. 16. 1628625–1628625.

Li, Tingting, et al.. (2025). Esketamine versus sufentanil as analgesics for sedation during painless gastrointestinal endoscopy: a double-blinded randomized controlled trial. Trials. 26(1). 425–425.

Li, Q., et al.. (2025). The impact of biologics targeting the IL-17 and IL-23 pathways on metabolic indicators in plaque psoriasis. Archives of Dermatological Research. 317(1). 643–643. 2 indexed citations

Wang, Xia, Dawei Chen, Ning Yao, et al.. (2024). Oxytocin Alleviates Colitis and Colitis-Associated Colorectal Tumorigenesis via Noncanonical Fucosylation. Research. 7. 407–407. 3 indexed citations

Li, Q., et al.. (2024). The improvement of pain symptoms in patients with burning mouth syndrome through combined laser and medication therapy. Technology and Health Care. 32(S1). 501–509. 3 indexed citations

Lee, Daniel J., Christine M. Lovly, Özgür Özyılkan, et al.. (2024). LBA2 SKYSCRAPER-06: Efficacy and safety of tiragolumab plus atezolizumab plus chemotherapy (tira + atezo + chemo) vs pembrolizumab plus chemotherapy (pembro + chemo) in patients (pts) with advanced non-squamous non-small cell lung cancer (NSq NSCLC). Immuno-Oncology Technology. 24. 101025–101025. 5 indexed citations

Birring, Surinder S., Peter V. Dicpinigaitis, Lorcan McGarvey, et al.. (2021). Baseline Cough Severity and Quality of Life in Patients with Chronic Cough Participating in Two Global Phase 3 Randomized Controlled Clinical Trials. A2359–A2359. 1 indexed citations

Smith, John A., Alyn H. Morice, Lorcan McGarvey, et al.. (2021). Objective Cough Frequency with Gefapixant in Chronic Cough: A Pooled Analysis of Two Phase 3 Randomized, Controlled Clinical Trials (COUGH-1 and COUGH-2). A2353–A2353. 1 indexed citations

Birring, Surinder S., AH Morice, John A. Smith, et al.. (2021). Responder Analyses for Patient-Reported Outcomes in a Pooled Analysis of Two Phase III Randomized Placebo Controlled Trials of Gefapixant, a P2X3 Receptor Antagonist for the Treatment of Chronic Cough. Research Portal (Queen's University Belfast). A2354–A2354. 1 indexed citations

10.

Kimball, Alexa B., Kim Papp, Kristian Reich, et al.. (2019). Efficacy and safety of tildrakizumab for plaque psoriasis with continuous dosing, treatment interruption, dose adjustments and switching from etanercept: results from phase III studies. British Journal of Dermatology. 182(6). 1359–1368. 23 indexed citations

11.

Papp, Kim, Kristian Reich, Andrew Blauvelt, et al.. (2019). Efficacy of tildrakizumab for moderate‐to‐severe plaque psoriasis: pooled analysis of three randomized controlled trials at weeks 12 and 28. Journal of the European Academy of Dermatology and Venereology. 33(6). 1098–1106. 19 indexed citations

12.

Blauvelt, Andrew, Kristian Reich, Kim Papp, et al.. (2018). Safety of tildrakizumab for moderate-to-severe plaque psoriasis: pooled analysis of three randomized controlled trials. British Journal of Dermatology. 179(3). 615–622. 60 indexed citations

13.

Crowley, Jeffrey, Kim Papp, Alan M. Mendelsohn, et al.. (2018). AB0903 Efficacy of tildrakizumab in etanercept partial or nonresponders. Annals of the Rheumatic Diseases. 77. 1575–1576. 1 indexed citations

14.

Crowley, Jeffrey, C. Leonardi, Alan Menter, et al.. (2018). SAT0312 Incidence of infections in clinical trials of tildrakizumab for moderate to severe chronic plaque psoriasis. Annals of the Rheumatic Diseases. 77. 1020–1021. 1 indexed citations

15.

Blauvelt, Andrew, Howard Sofen, Kim Papp, et al.. (2018). AB0955 Tildrakizumab efficacy over time by week 28 response levels in two phase 3 clinical trials in patients with chronic plaque psoriasis. Annals of the Rheumatic Diseases. 77. 1602–1603. 2 indexed citations

16.

Gooderham, Melinda, Boni E. Elewski, David M. Pariser, et al.. (2018). THU0291 Incidence of serious gastrointestinal events and inflammatory bowel disease among tildrakizumab-treated patients with moderate to severe plaque psoriasis: data from 3 large randomised clinical trials. Annals of the Rheumatic Diseases. 77. 364–364. 1 indexed citations

17.

Barlési, Fabrice, Edward B. Garon, Dongwook Kim, et al.. (2016). Assessment of health-related quality of life (HRQoL) in KEYNOTE-010: A phase 2/3 study of pembrolizumab vs docetaxel in patients with previously treated advanced NSCLC. Annals of Oncology. 27. vi422–vi422. 9 indexed citations

18.

Thaçi, Diamant, Kim Papp, Kristian Reich, et al.. (2016). FRI0446 Treatment with Tildrakizumab, An Anti-IL-23P19 Monoclonal Antibody, Improves Health-Related Quality of Life in Patients with Chronic Plaque Psoriasis. Annals of the Rheumatic Diseases. 75. 597–597. 2 indexed citations

19.

Langley, Richard G., Diamant Thaçi, Kristian Reich, et al.. (2016). FRI0445 Tildrakizumab Treatment Improved Measures of Psoriatic Arthritis in Adults with Chronic Plaque Psoriasis. Annals of the Rheumatic Diseases. 75. 596–597. 5 indexed citations

20.

Papp, Kim, Diamant Thaçi, Kristian Reich, et al.. (2015). Tildrakizumab (MK-3222), an anti-interleukin-23p19 monoclonal antibody, improves psoriasis in a phase IIb randomized placebo-controlled trial. British Journal of Dermatology. 173(4). 930–939. 228 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact